S156
Brachytherapy - Urology
ESTRO 2026
permanent catheterization. Conclusion: MRI–based HDR prostate brachytherapy was successfully implemented and integrated into routine clinical practice at our Institute. The technique demonstrated excellent target coverage, consistent adherence to OAR constraints and acceptable acute toxicity, confirming its feasibility and safety across diverse clinical indications. Keywords: prostate brachytherapy, HDR, implementation Digital Poster Highlight 858 Prospective phase II multicenter trial of high-dose- rate brachytherapy for prostate cancer. Koji Inaba 1 , Yasuo Yoshioka 2 , Hiromichi Ishiyama 3 , Ken Yoshida 4 , Tairo Kashihara 1 , Hiroaki Kunogi 2 , Hideyasu Tsumura 5 , Tadayuki Kotsuma 6,7 , Akira Komiya 8 , Saiji Ooga 9 , Satoaki Nakamura 10 , Shingo Kato 11 , Hiroshi Igaki 1 , Jun Itami 12 1 Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. 2 Radiation Oncology Department, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 3 Department of Radiation Oncology, Kitasato University School of Medicine, Kanagawa, Japan. 4 Department of Radiology, Kansai Medical University Medical Center, Osaka, Japan. 5 Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. 6 Department of Radiation Oncology, NHO Osaka National Hospital, Osaka, Japan. 7 Department of Radiation Oncology, Osaka Rosai Hospital, Sakai, Japan. 8 Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. 9 Department of Radiation Therapy, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. 10 Department of Radiology, Kansai Medical University, Osaka, Japan. 11 Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan. 12 Shin-Matsudo Accuracy Radiation Therapy Center, Shin-Matsudo Central General Hospital, Chiba, Japan Purpose/Objective: High-dose-rate (HDR) brachytherapy is widely used for prostate cancer. Although typically indicated for low- to intermediate-risk disease, its highly conformal dose distribution suggests potential applicability to high- and very high-risk disease. This prospective Phase II multicenter trial evaluated the safety and efficacy of HDR brachytherapy in patients with low- to very high- risk prostate cancer. Material/Methods: Patients with histologically confirmed prostate adenocarcinoma (T1c–T3bN0M0), PSA <50 ng/mL, and
The most common acute complication was hematuria immediately after applicator removal, occurring in 30% of procedures (18/61), typically resolving within minutes or the following day. Delayed hematuria (starting the day after treatment) occurred in 8% (5/61) and resolved within days to weeks. Acute urinary retention developed in 4 patients, one requiring
Made with FlippingBook - Share PDF online